1021919-24-3

Basic information

• Product Name: tert-Butyl 4-bromo-3-methyl-1H-pyrazole-1-carboxylate
• Synonyms: 1-BOC-4-Bromo-3-methylpyrazole;tert-Butyl 4-bromo-3-methyl-1H-pyrazole-1-carboxylate
• CAS NO: 1021919-24-3
• Molecular Formula: C₉H₁₃BrN₂O₂
• Molecular Weight: 261.11572
• Mol File: 1021919-24-3.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Storage Temp.: Refrigerated.
• CAS DataBase Reference: tert-Butyl 4-bromo-3-methyl-1H-pyrazole-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-Butyl 4-bromo-3-methyl-1H-pyrazole-1-carboxylate(1021919-24-3)
• EPA Substance Registry System: tert-Butyl 4-bromo-3-methyl-1H-pyrazole-1-carboxylate(1021919-24-3)

Safety Data

• Hazardous Substances Data: 1021919-24-3(Hazardous Substances Data)

Usage

General Description

Tert-Butyl 4-bromo-3-methyl-1H-pyrazole-1-carboxylate is a chemical compound with the molecular formula C8H12BrN3O2. It is a pyrazole derivative with a tert-butyl group attached to the pyrazole ring. The compound also contains a bromine atom and a methyl group, as well as a carboxylic ester group. This chemical may have applications in pharmaceutical and chemical research due to its unique structure and potential biological activities. Additionally, it may be used as an intermediate in the synthesis of other organic compounds. However, because of its bromine substituent, it is important to handle this chemical with caution and adhere to proper safety protocols.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 92276-46-5 4-bromo-3-methyl-1⁽²⁾H-pyrazole; hydrobromide 
• 13808-64-5 4-bromo-3-methyl-1H-pyrazole 

Downstream Products

• 1009071-34-4 tert-butyl 3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole-1-carboxylate 
• 1140502-26-6 C₂₉H₂₈ClN₅O₄S 
• 936250-20-3 3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole 

Relevant articles and documents

BIPYRAZOLE DERIVATIVES AS JAK INHIBITORS

The present invention provides compounds of Formula I: or pharmaceutically acceptable salts thereof, as well as their compositions and methods of use, that inhibit the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.

THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS

The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, or a prodrug thereof, which is useful for the prophylaxis or treatment of cancer

Substituted furo[2,3-B] pyridine derivatives as cannabinoid-1 receptor modulators

Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, Alzheimer's disease, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, cirrhosis of the liver, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and the promotion of wakefulness.